Request for Information: AHRQ's Proposed Patient-Centered Outcomes Research Trust Fund Strategic Framework, 9360-9362 [2022-03551]
Download as PDF
<![CDATA[
9360
Federal Register / Vol. 87, No. 34 / Friday, February 18, 2022 / Notices
B. Need and Uses
This clearance covers the information
that contractors must submit to comply
with the following Federal Acquisition
Regulation (FAR) requirements:
• FAR 52.248–1, Value Engineering;
52.248–2, Value Engineering-ArchitectEngineer; and 52.248–3, Value
Engineering-Construction.
These clauses require contractors
submitting Value Engineering Change
Proposals (VECP’s) to the Government
to provide such details as: (1) A
description of the differences between
the existing contract requirement and
the proposed requirement, and the
comparative advantages and
disadvantages of each; (2) a list and
analysis of contract requirements that
must be changed if the VECP is
accepted; (3) a detailed cost estimate
showing anticipated reductions
associated with the VECP; (4) a
statement of the time a modification
accepting the VECP must be issued to
achieve maximum cost reduction, and
the effect on contract completion time;
and (5) identification of any previous
submissions of the VECP; the agencies
and contract numbers involved and
previous Government actions, if known.
The Government will use the
collected information to evaluate the
VECP and, if accepted, to arrange for an
equitable sharing plan.
C. Annual Burden
Respondents: 109.
Total Annual Responses: 218.
Total Burden Hours: 3,270.
Obtaining Copies: Requesters may
obtain a copy of the information
collection documents from the GSA
Regulatory Secretariat Division by
calling 202–501–4755 or emailing
GSARegSec@gsa.gov. Please cite OMB
Control No. 9000–0027, Value
Engineering Requirements.
Janet Fry,
Director, Federal Acquisition Policy Division,
Office of Governmentwide Acquisition Policy,
Office of Acquisition Policy, Office of
Governmentwide Policy.
[FR Doc. 2022–03561 Filed 2–17–22; 8:45 am]
jspears on DSK121TN23PROD with NOTICES1
BILLING CODE 6820–EP–P
VerDate Sep<11>2014
18:54 Feb 17, 2022
Jkt 256001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Request for Information: AHRQ’s
Proposed Patient-Centered Outcomes
Research Trust Fund Strategic
Framework
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice of request for
information.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
input from the public on its proposed
strategic framework for AHRQ’s PatientCentered Outcomes Research Trust
Fund investments.
DATES: Comments on this notice must be
received by April 19, 2022. AHRQ will
not respond individually to responders
but will consider all comments
submitted by the deadline.
ADDRESSES: Please submit all responses
via email to: PCORTF@ahrq.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
Karin Rhodes, MD, Chief
Implementation Officer, Email:
PCORTF@ahrq.hhs.gov, Telephone:
301–427–1364 or 240–463–0872.
SUPPLEMENTARY INFORMATION: AHRQ is
authorized under 42 U.S.C. 299b–37 to
broadly disseminate patient-centered
outcomes research (PCOR) findings,
including incorporation of PCOR
findings into health information
technology focused on clinical decision
support, and to train researchers in the
methods used to conduct PCOR. PCOR
compares the impact of two or more
preventive, diagnostic, treatment, or
healthcare delivery approaches on
health outcomes, including those that
are meaningful to patients. AHRQ’s
work under 42 U.S.C. 299b–37 is funded
by the Patient-Centered Outcomes
Research Trust Fund (PCORTF), 26
U.S.C. 9511, which was established in
2010 and reauthorized in 2019. To learn
more about the PCORTF, please visit:
https://www.ahrq.gov/pcor/potential-ofthe-pcortf/.
SUMMARY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
In response to the reauthorization of
the PCORTF, AHRQ has developed a
proposed strategic framework to guide
future planning and evaluation of
AHRQ’s PCORTF investments (the
strategic framework). The strategic
framework is consistent with AHRQ’s
broader goal of improving the quality,
safety, equity, and value of healthcare
delivery.
The proposed strategic framework
identifies five priorities for improving
healthcare delivery that are aligned with
AHRQ’s mission and that have the
potential to improve outcomes that
patients care about. These priorities are
interrelated, and all contribute to
achieving the proposed strategic
framework’s overall vision of equitable
whole-person care across the lifespan.
The proposed strategic framework is
consistent with AHRQ’s Congressional
authorization for investments from the
PCORTF and is aligned with national
health priorities.
The AHRQ PCORTF strategic
framework includes a mission, vision,
high-level priorities, desired outcomes,
and cross-cutting strategies for
advancing the desired outcomes. This
framework is expected to describe and
inform the portfolio of AHRQ PCORTF
investments. AHRQ will use this broad
framework to guide long-range planning
and to guide the development of
projects and investments.
AHRQ PCORTF-funded projects will
be connected to components and subcomponents of the strategic framework.
Use of the strategic framework is
intended to ensure that AHRQ’s
investments are coherently connected
and advance the overall vision of
advancing equitable whole-person care
across the lifespan. The final strategic
framework will also provide a basis for
creating an evaluation framework,
measuring the success of individual
projects, and identifying the overall
impact of AHRQ’s PCORTF
investments.
AHRQ is seeking public comment on
the proposed strategic framework for
AHRQ’s PCORTF investments.
BILLING CODE 4160–90–P
E:\FR\FM\18FEN1.SGM
18FEN1
jspears on DSK121TN23PROD with NOTICES1
BILLING CODE 4160–90–C
AHRQ hopes to receive feedback from
patients, healthcare professionals,
community groups, employers, health
services researchers, dissemination and
implementation scientists,
communications experts,
representatives from health systems,
public and private payers, and other
stakeholders.
The input received from this public
comment period will be used in refining
and finalizing the strategic framework.
Based on the final strategic framework,
AHRQ intends to develop an
operational plan, which will include
specific short- and long-term objectives
and a formative and summative
evaluation. The overall goal of AHRQ’s
planning process is to identify
investments consistent with its PCORTF
authorization that will have the greatest
positive impact on health and
healthcare.
AHRQ is requesting information from
the public regarding the following broad
questions:
1. AHRQ would like overall reactions
to the strategic framework; is there any
aspect of the framework that:
VerDate Sep<11>2014
18:54 Feb 17, 2022
Jkt 256001
a. Does not promote the vision of
advancing equitable whole-person care
across the lifespan?
b. Does not address major challenges
faced by the U.S. healthcare system?
c. Could be improved (and if so,
how)?
2. AHRQ would like input on our
(non-ranked) high-level priority areas:
a. Do our proposed high-level
priorities miss any areas of critical
importance?
b. Are any of the high-level priorities
more important than others?
3. AHRQ would like input on how to
target investments within high-priority
areas. For example, should AHRQ focus
on:
a. Specific ages/stages or apply
AHRQ’s investments equally across the
lifespan?
b. Transitions in care?
4. AHRQ would also appreciate
suggestions for applying the strategic
framework. For example:
a. How can AHRQ improve the
dissemination of patient-centered
outcomes research evidence to decisionmakers at the local, State, and Federal
levels?
b. What targeted investments could
AHRQ make to sustain progress towards
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
9361
the strategic framework’s desired
outcomes?
c. What AHRQ PCORTF investments
could help improve healthcare provider
trust, well-being, and retention?
5. How can AHRQ have the greatest
impact and success at achieving the
vision and mission of the strategic
framework?
a. What is the most effective way to
ensure the sustainability of initiatives
that seek to enhance the integration of
patient-centered outcomes research
findings into practice?
b. What complementary partnerships
and collaborations (both public and
private) would increase the impact of
AHRQ’s PCORTF investments?
c. What will be the best way of
measuring progress and the overall
impact of AHRQ’s PCORTF
investments?
6. Is there anything else you would
like to share regarding the strategic
framework?
AHRQ is interested in all of the
questions listed above, but respondents
are welcome to address as many or as
few as they choose and to address
additional areas of interest not listed. It
is helpful to identify which question a
particular answer is a response to.
E:\FR\FM\18FEN1.SGM
18FEN1
EN18FE22.000</GPH>
Federal Register / Vol. 87, No. 34 / Friday, February 18, 2022 / Notices
9362
Federal Register / Vol. 87, No. 34 / Friday, February 18, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES1
This RFI is for planning purposes
only and should not be construed as a
policy, solicitation for applications, or
as an obligation on the part of the
Government to provide support for any
ideas identified in response to it. AHRQ
will use the information submitted in
response to this RFI at its discretion and
will not provide comments to any
responder’s submission. However,
responses to the RFI may be reflected in
future solicitation(s) or policies. The
information provided will be analyzed
and may appear in reports. Respondents
will not be identified in any published
reports. Respondents are advised that
the Government is under no obligation
to acknowledge receipt of the
information received or provide
feedback to respondents with respect to
any information submitted. No
proprietary, classified, confidential, or
sensitive information should be
included in your response. The contents
of all submissions will be made
available to the public upon request.
Materials submitted must be publicly
available or able to be made public.
Collaborative: Using Data to Promote the
Health and Wellness of People with
Disabilities.
Date: May 3, 2022.
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman, Ph.D., Scientific Review Officer,
National Center for Chronic Disease
Prevention and Health Promotion, CDC,
4770 Buford Highway, Mailstop S107–
B, Atlanta, Georgia 30341, Telephone:
(770) 488–6511, Email: JRaman@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: February 15, 2022.
Marquita Cullom,
Associate Director.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–03551 Filed 2–17–22; 8:45 am]
[FR Doc. 2022–03554 Filed 2–17–22; 8:45 am]
BILLING CODE 4160–90–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—RFA–PS–22–
001, Implementing Pre-Exposure
Prophylaxis for HIV Prevention in
Syringe Service Programs; RFA–PS–
22–002, Implementation Research on
Telehealth Strategies To Support
Retention in Care and Treatment
Among Antiretroviral Therapy (ART)
Patients and Pre-Exposure Prophylaxis
(PrEP) Clients and RFA–PS–22–004,
Understanding HIV/STD Risk and
Enhancing PrEP Implementation
Messaging in a Diverse CommunityBased Sample of Gay, Bisexual, and
Other Men Who Have Sex With Men in
a Transformational Era; Amended
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
SIP22–004, Disability and Health Data
VerDate Sep<11>2014
18:54 Feb 17, 2022
Jkt 256001
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP) RFA–PS–
22–001, Implementing Pre-exposure
Prophylaxis for HIV Prevention in
Syringe Service Programs; RFA–PS–22–
002, Implementation Research on
PO 00000
Frm 00056
Fmt 4703
Sfmt 9990
Telehealth Strategies to support
Retention in Care and Treatment among
Antiretroviral Therapy (ART) Patients
and Pre-exposure Prophylaxis (PrEP)
Clients; and RFA–PS–22–004,
Understanding HIV/STD Risk and
Enhancing PrEP Implementation
Messaging in a Diverse CommunityBased Sample of Gay, Bisexual, and
Other Men Who Have Sex with Men in
a Transformational Era.
Date: March 30, 2022.
Time: 10:00 a.m.–5:00 p.m. (EDT).
Place: Teleconference.
The meeting was published in the
Federal Register on February 4, 2022,
Volume 87, Number 24, page 6562–
6563.
The meeting is being amended to
remove RFA–PS–22–002,
Implementation Research on Telehealth
Strategies to Support Retention in Care
and Treatment among Antiretroviral
Therapy (ART) Patients and Preexposure Prophylaxis (PrEP) Clients and
should read as follows:
RFA–PS–22–001, Implementing Preexposure Prophylaxis for HIV
Prevention in Syringe Service Programs
and RFA–PS–22–004, Understanding
HIV/STD Risk and Enhancing PrEP
Implementation Messaging in a Diverse
Community-Based Sample of Gay,
Bisexual, and Other Men Who Have Sex
with Men in a Transformational Era.
The meeting is closed to the public.
For Further Information Contact:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, National
Center for HIV, Viral Hepatitis, STD,
and TB Prevention, CDC, 1600 Clifton
Road NE, Mailstop US8–1, Atlanta,
Georgia 30329, Telephone: (404) 718–
8833, Email: GAnderson@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–03555 Filed 2–17–22; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\18FEN1.SGM
18FEN1
]]>Agencies
[Federal Register Volume 87, Number 34 (Friday, February 18, 2022)]
[Notices]
[Pages 9360-9362]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03551]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Request for Information: AHRQ's Proposed Patient-Centered
Outcomes Research Trust Fund Strategic Framework
AGENCY: Agency for Healthcare Research and Quality, HHS.
ACTION: Notice of request for information.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking input from the public on its proposed strategic framework for
AHRQ's Patient-Centered Outcomes Research Trust Fund investments.
DATES: Comments on this notice must be received by April 19, 2022. AHRQ
will not respond individually to responders but will consider all
comments submitted by the deadline.
ADDRESSES: Please submit all responses via email to:
[email protected].
FOR FURTHER INFORMATION CONTACT: Karin Rhodes, MD, Chief Implementation
Officer, Email: [email protected], Telephone: 301-427-1364 or 240-
463-0872.
SUPPLEMENTARY INFORMATION: AHRQ is authorized under 42 U.S.C. 299b-37
to broadly disseminate patient-centered outcomes research (PCOR)
findings, including incorporation of PCOR findings into health
information technology focused on clinical decision support, and to
train researchers in the methods used to conduct PCOR. PCOR compares
the impact of two or more preventive, diagnostic, treatment, or
healthcare delivery approaches on health outcomes, including those that
are meaningful to patients. AHRQ's work under 42 U.S.C. 299b-37 is
funded by the Patient-Centered Outcomes Research Trust Fund (PCORTF),
26 U.S.C. 9511, which was established in 2010 and reauthorized in 2019.
To learn more about the PCORTF, please visit: https://www.ahrq.gov/pcor/potential-of-the-pcortf/.
In response to the reauthorization of the PCORTF, AHRQ has
developed a proposed strategic framework to guide future planning and
evaluation of AHRQ's PCORTF investments (the strategic framework). The
strategic framework is consistent with AHRQ's broader goal of improving
the quality, safety, equity, and value of healthcare delivery.
The proposed strategic framework identifies five priorities for
improving healthcare delivery that are aligned with AHRQ's mission and
that have the potential to improve outcomes that patients care about.
These priorities are interrelated, and all contribute to achieving the
proposed strategic framework's overall vision of equitable whole-person
care across the lifespan. The proposed strategic framework is
consistent with AHRQ's Congressional authorization for investments from
the PCORTF and is aligned with national health priorities.
The AHRQ PCORTF strategic framework includes a mission, vision,
high-level priorities, desired outcomes, and cross-cutting strategies
for advancing the desired outcomes. This framework is expected to
describe and inform the portfolio of AHRQ PCORTF investments. AHRQ will
use this broad framework to guide long-range planning and to guide the
development of projects and investments.
AHRQ PCORTF-funded projects will be connected to components and
sub-components of the strategic framework. Use of the strategic
framework is intended to ensure that AHRQ's investments are coherently
connected and advance the overall vision of advancing equitable whole-
person care across the lifespan. The final strategic framework will
also provide a basis for creating an evaluation framework, measuring
the success of individual projects, and identifying the overall impact
of AHRQ's PCORTF investments.
AHRQ is seeking public comment on the proposed strategic framework
for AHRQ's PCORTF investments.
BILLING CODE 4160-90-P
[[Page 9361]]
[GRAPHIC] [TIFF OMITTED] TN18FE22.000
BILLING CODE 4160-90-C
AHRQ hopes to receive feedback from patients, healthcare
professionals, community groups, employers, health services
researchers, dissemination and implementation scientists,
communications experts, representatives from health systems, public and
private payers, and other stakeholders.
The input received from this public comment period will be used in
refining and finalizing the strategic framework. Based on the final
strategic framework, AHRQ intends to develop an operational plan, which
will include specific short- and long-term objectives and a formative
and summative evaluation. The overall goal of AHRQ's planning process
is to identify investments consistent with its PCORTF authorization
that will have the greatest positive impact on health and healthcare.
AHRQ is requesting information from the public regarding the
following broad questions:
1. AHRQ would like overall reactions to the strategic framework; is
there any aspect of the framework that:
a. Does not promote the vision of advancing equitable whole-person
care across the lifespan?
b. Does not address major challenges faced by the U.S. healthcare
system?
c. Could be improved (and if so, how)?
2. AHRQ would like input on our (non-ranked) high-level priority
areas:
a. Do our proposed high-level priorities miss any areas of critical
importance?
b. Are any of the high-level priorities more important than others?
3. AHRQ would like input on how to target investments within high-
priority areas. For example, should AHRQ focus on:
a. Specific ages/stages or apply AHRQ's investments equally across
the lifespan?
b. Transitions in care?
4. AHRQ would also appreciate suggestions for applying the
strategic framework. For example:
a. How can AHRQ improve the dissemination of patient-centered
outcomes research evidence to decision-makers at the local, State, and
Federal levels?
b. What targeted investments could AHRQ make to sustain progress
towards the strategic framework's desired outcomes?
c. What AHRQ PCORTF investments could help improve healthcare
provider trust, well-being, and retention?
5. How can AHRQ have the greatest impact and success at achieving
the vision and mission of the strategic framework?
a. What is the most effective way to ensure the sustainability of
initiatives that seek to enhance the integration of patient-centered
outcomes research findings into practice?
b. What complementary partnerships and collaborations (both public
and private) would increase the impact of AHRQ's PCORTF investments?
c. What will be the best way of measuring progress and the overall
impact of AHRQ's PCORTF investments?
6. Is there anything else you would like to share regarding the
strategic framework?
AHRQ is interested in all of the questions listed above, but
respondents are welcome to address as many or as few as they choose and
to address additional areas of interest not listed. It is helpful to
identify which question a particular answer is a response to.
[[Page 9362]]
This RFI is for planning purposes only and should not be construed
as a policy, solicitation for applications, or as an obligation on the
part of the Government to provide support for any ideas identified in
response to it. AHRQ will use the information submitted in response to
this RFI at its discretion and will not provide comments to any
responder's submission. However, responses to the RFI may be reflected
in future solicitation(s) or policies. The information provided will be
analyzed and may appear in reports. Respondents will not be identified
in any published reports. Respondents are advised that the Government
is under no obligation to acknowledge receipt of the information
received or provide feedback to respondents with respect to any
information submitted. No proprietary, classified, confidential, or
sensitive information should be included in your response. The contents
of all submissions will be made available to the public upon request.
Materials submitted must be publicly available or able to be made
public.
Dated: February 15, 2022.
Marquita Cullom,
Associate Director.
[FR Doc. 2022-03551 Filed 2-17-22; 8:45 am]
BILLING CODE 4160-90-P
